

October 26, 2020

|   |   |
|---|---|
| DCS-CRD<br>BSE Limited<br>First Floor, New Trade Wing<br>Rotunda Building,<br>Phiroze Jeejeebhoy Towers<br>Dalal Street, Fort<br>Mumbai 400 023<br>Fax No.2272 3121/2037/2039<br><br>Stock Code: 543213 | Listing Compliance<br>National Stock Exchange of India Ltd.<br>Exchange Plaza, 5th Floor<br>Plot No.C/1, 'G'Block<br>Bandra- Kurla Complex<br>Bandra East<br>Mumbai 400 051<br>Fax No.2659 8237/8238<br><br>Stock Code: ROSSARI |
|---|---|

Dear Sir/Madam,

**Sub: News Paper Publication of Extracts of Consolidated Unaudited Financial Results and Statement of Deviation or Variation for the quarter ended September 30, 2020**

Pursuant to the Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copies each of Financial Express (English Daily) and Loksatta (Marathi Daily) both dated October 25, 2020 for publication of extracts of Consolidated Unaudited Financial Results and Statement of Deviation or Variation for the quarter ended September 30, 2020.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,  
**For Rossari Biotech Limited**



Parul Gupta  
**Company Secretary & Compliance Officer**  
Membership No.: A38895

Encl.: as above

**ROSSARI BIOTECH LIMITED**

(An ISO 9001:2015 & 14001:2015 Certified Company)

Regd. Office : 201 A & B, Akruti Corporate Park, Next to GE Gardens, LBS Marg, Kanjurmarg (W). Mumbai - 400078. India. T +91-22-6123 3800 F +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/11/1, Kumbharwadi, Village Naroli, Dadra & Nagar Haveli (U.T.), Silvassa - 396 235. India. T 0260 - 669 3000

E info@rossarimail.com W www.rossari.com CIN: U24100MH2009PLC194818

From the Front Page

After customers, now dealers make most of telcom rivalry

The company is also offering cashbacks to customers in case they opt to join their network. The incentives and cashbacks vary with telcom circles. Vodafone Idea has already decided to concentrate on circles where it has strong network and good market share. A query sent to Bharti Airtel regarding the dealer margins remained unanswered while Vodafone Idea said its incentives and commissions are in line with the industry practice. Many dealers also said that Reliance Jio has so far not revised its commission policy. Sources in the company told Financial Express that they are closely watching the developments in the industry and any call around dealer commission will be taken at an appropriate time. The company did not answer a query asking if it has increased the commission for dealers. As a result of such aggressive sales practices, MNP requests increased to 7.53 million in July, the highest seen since March 2018. Live events resume, but the spark is missing While music concerts, the-

atrical productions, sporting events and festivals require a certain level of production, owing to their scale, comedy events could work well with intimate settings. The ceiling on number of attendees and implementation of hygiene best practices are two factors that are holding organisers back. "Our cost has gone up by 38%, mainly due to all the hygiene and safety protocols that we need to invest in. And our revenues are down by 60-70% because of the cap on attendees," says Swaroop Banerjee, COO and business head, Zee Live. Sponsored by Škoda Auto, Zee Live recently held a three-day drive-in theatre movie premiere for Khaali Peeli. Zee Live is also planning to introduce formats like cubicle concerts, where groups of four people can sit in a cubicle and watch an event. That apart, organisers are unable to raise ticket prices. As per industry estimates, prices of tickets have fallen to a third of their pre-Covid levels. In order to build consumer confidence, organisers are keeping the prices pocket-friendly, and looking to enlist the support of brands and sponsors. Banerjee points out that now events attract only up to four sponsors. This used to be as high as 12 for a marquee event in pre-Covid times. "The sponsors now cover about 50% of our costs. Earlier, this was 60-70%," he adds.

Durga Puja, which sees high interest from brands for activations, is not so attractive this year. Experts say overall sponsorship is down by 60% and most activations are happening in residential areas. AstraZeneca resumes trial, J&J next week J&J expects to resume its trial in the United States on Monday or Tuesday and remains on track to produce data from the trial on the vaccines' effectiveness by the end of 2020 or early 2021, J&J's chief scientific officer Paul Stoffels said. J&J is also in discussions with other regulators to resume a trial outside of the United States, the company said. So far, the medical board has not identified a clear cause for the patients' illness. J&J cannot reveal any details about the patient's sickness because of patient privacy rules, Stoffels said. AstraZeneca said that it is not unusual for some trial participants to fall ill during large scale vaccine trials but that the US Food and Drug Administration has reviewed all safety data from the trials globally and deemed it safe to continue testing the vaccine. Support from govt but not customers Though Google has for the

time being suspended this practice, a consortium of Indian app creators decided to challenge Google's monopoly. Paytm went ahead with creating its mini app store and convinced around 300 creators to list their apps on it. It even provided a demo of its app store on October 8. However, its success depends on its ability to wean off users from Google's Play, and here the government can do little. In India, Google Play has around 94% market share and accounts for 360 million unique visitors, according to Comscore data released in August. Data from 42 matters on app availability and developer preference for Google and Apple's platforms shows that even big names like Amazon and Tencent haven't been able to put up a competition. Google has 3.4 million apps on its Play store, whereas Apple has 1.7 million apps. They also have 0.8 million and 1.3 million developers, respectively. In contrast, Amazon has only a sixth of apps and developers. Tencent has an even lower share with 82,798 apps and 52,158 developers. India's native app store, Indus App Bazaar, which also offers translation services to apps in 12 Indian languages, has been modestly successful but still nowhere near Google or Apple. The company claims to

have 400,000 apps and 56 million monthly active users. Analysts say this could be due to the company running its operating system for mobile phones and its partnership with Samsung to populate Samsung's Galaxy Store. Still, with around 100 million users, it only forms a fraction of Android's 2.5 billion or Apple's 1.4 billion global active user base. Gartner's senior research director Manjunath Bhat told FE that other app stores cannot match Google's Play as they lack 'network effects'. "Google Play is mandatory to make use of Google mobile services that includes other apps like Maps. Any Android-based OEM device comes pre-bundled with Google Play, which provides users with a secure, reliable and familiar access path to download apps. An app store is fundamentally a marketplace, and a marketplace thrives as a result of both producers and consumers actively contributing to the growth of the market." Interest relief scheme notified Also, the ex-gratia will be available to borrowers subject to conditions that a loan account should be standard as on February 29 and the prevailing interest rates on that date would be factored in the

relief. Other conditions include lending institution must be either a banking company, or a public sector bank, or a co-operative bank, or a regional rural bank, or an all India financial institution, or a non-banking financial company or a housing finance company registered with RBI or national housing bank as the case may be. A non-banking financial company—micro finance institution should be a member of a Self-Regulatory Organisation (SRO) recognised by RBI. The lending institutions would have to lodge claim for reimbursement for the amount spent on the scheme from the Centre by December 15. As reported by FE earlier, the government had stated in an affidavit that extending the interest relief to all "all types of loans for all categories of borrowers" would cause a huge burden of ₹6 lakh crore on banks, likely wiping out a major part of their net worth and even rendering most of them unviable. The RBI also concurred with the government's views in this regard. The government and RBI had recently ruled out any further waiver of interest on interest, or compounding as this will entail significant economic costs which cannot be absorbed by the banks without serious dent to their financials, which in turn will have huge implications for

the depositors and the broader financial stability. According to the DFS notification, for education loans, housing loans, automobile loans, personal loans to professionals, consumption loans, the rate of interest to be applied for calculating the difference between simple and compound interest shall be the contracted rate as specified in loan agreement/documentation in this respect. For consumer durable loans, the rate of interest to be applied for calculating the difference between simple and compound interest shall be the contracted rate as specified in loan agreement/documentation. For credit card dues, the rate of interest shall be the weighted average lending rate (WALR) charged by the card issuer for transactions financed on EMI basis from its customers during the period from March 1 to August 31. For MSME loans, the rate of interest to be applied for calculating the difference between simple and compound interest shall be the contracted rate as specified in loan agreement/documentation in respect of the term loan. For cash credit (CC) / overdraft (OD), the rate of interest would be as prevailing on February 29, 2020. Penal interest or penalty for late payment would not be reckoned as part of the contracted rate or WALR.

'China says looking into unfair competition on e-commerce platforms'

REUTERS Shanghai, October 24 CHINA'S MARKET REGULATOR and other government departments have launched an exercise focused on e-commerce, with plans to crack down on areas such as unfair competition and the illegal trading of counterfeit or wildlife, state news agency Xinhua said. The operation will run until December and will also look into areas such as livestreaming, which has in the past two years become a popular sales channel in China, Xinhua said on Saturday, referring to a recent issued notice from the State Administration of Market Supervision and other departments. A file photo of workers sorting parcels at a cross-border e-commerce industrial park in Hefei, Anhui province, China

'US monitoring border row between India and China'

PRESS TRUST OF INDIA Washington, October 24 THE US IS closely monitoring the border row between India and China and does not want the situation to escalate, a senior Trump administration official has said. The official told the reporters during a conference call on Friday, ahead of the next week's 2+2 India-US Ministerial in New Delhi, that the Trump administration was providing support to India

through defence sales, joint military exercises and information sharing. "We as a government are covering the situation in the Himalayas closely, and understandably. We certainly want to ensure that the situation doesn't escalate," the official said. "These are all areas where we cooperate with the Indians on, and not just as it relates to the tensions in the Himalayas," the official said. India and China are locked in a bitter border

standoff in eastern Ladakh since early May that has significantly strained the bilateral ties. Both sides have held a series of diplomatic and military talks to resolve the row. However, no breakthrough has been achieved to end the standoff. China unsuccessfully attempted to occupy Indian territory on the southern bank of Pangong Lake in the last week of August. In response to a question, the official, who spoke on the condition of anonymity, said that the US was having an ongoing dialogue with India about increased cooperation in south-east

Asia, and not simply about the South China Sea. "And we encourage their involvement. That cuts across development investments, it cuts across security cooperation, and then it also involves presence. So, we welcome greater Indian participation in Southeast Asia across all three of those areas," said the official. The senior official's remarks came in the midst of a growing global concern over China's expansionist behaviour.

standoff in eastern Ladakh since early May that has significantly strained the bilateral ties. Both sides have held a series of diplomatic and military talks to resolve the row. However, no breakthrough has been achieved to end the standoff. China unsuccessfully attempted to occupy Indian territory on the southern bank of Pangong Lake in the last week of August. In response to a question, the official, who spoke on the condition of anonymity, said that the US was having an ongoing dialogue with India about increased cooperation in south-east

**COCHIN MINERALS AND RUTILE LTD.** (100% E.O.U.) AN ISO 9001:2015 Company. Regd. Office: P.B. No. 73, VIII/224, Market Road, Aluva - 683 101, Kerala, India. Ph: 0484-2626789 CIN: L24299KL1989PLC005452

**NOTICE**  
A meeting of the Board of Directors of the Company, which will, inter alia, consider the Unaudited Financial Results for the Quarter and half year ended 30<sup>th</sup> September, 2020 will be held on Saturday, 07<sup>th</sup> November, 2020 at 11.30 A.M. at the Registered Office of the Company at Aluva.

Sd/-  
**P. Suresh Kumar**  
C.G.M (Finance) & Company Secretary  
Aluva  
23.10.2020

**ROSSARI BIOTECH LIMITED**  
(AN ISO9001:2005 & 14001:2015 Certified Company)  
CIN : U24100MH2009PLC194818  
Regd. Office : 201 A & B, 2<sup>nd</sup> Floor, Akruvi Corporate Park, L.B.S. Marg, Next to G. E. Gardens, Kanjurmarg (W) Mumbai - 400 078  
T: +91-22-6123 3800 F: +91-22- 25796982  
E: info@rossarimail.com W: www.rossari.com

**Statement of Deviation / Variation in utilization of funds raised**

| Name of listed entity  | ROSSARI BIOTECH LIMITED   |
|--|---|
| Mode of Fund Raising   | Public Issue (Initial Public Offer (IPO) & Pre-IPO)   |
| Date of Raising Funds  | 13 <sup>th</sup> July 2020 to 15 <sup>th</sup> July 2020  |
| Amount Raised  | Rs. 150 Crores*   |
| Report filed for Quarter ended   | 30th September 2020   |
| Monitoring Agency  | Applicable  |
| Monitoring Agency Name, if applicable  | Axis Bank Limited   |
| Is there a Deviation/Variation in use of funds raised  | No  |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | NA  |
| If yes, Date of shareholder Approval   | NA  |
| Explanation for Deviation/Variation  | NA  |
| Comments of the Audit Committee after review   | NA  |
| Comments of the auditors, if any   | No  |
| Objects for which funds have been raised and where there has been a deviation, in the following table                    | The net proceeds of the Fresh issue to be utilised for Repayment/Prepayment of certain indebtedness availed by the Company. Funding working capital requirement and general corporate purposes. No Deviation from objects |

| Original Object                            | Modified Object, if any | Original Allocation | Allocation Modified allocation, if any | Funds Utilised | Amount of Deviation/Variation for the quarter according to applicable object | Remarks if any |
|--|-------------------------|---------------------|--|----------------|--|----------------|
| Not Applicable as no deviation from object |                         |                     |  |                |  |                |

\* The IPO of the Company was for Rs. 496.25 Crores i.e. Rs. 50.00 Crores of Fresh Issue and Rs. 446.25 Crores of Offer for Sale. The Company has also raised an amount of Rs. 100.00 Cr. through Pre-IPO. Hence, the amount raised by the Company through IPO and Pre-IPO is Rs. 150.00 Crores.  
Deviation or variation could mean:  
a) Deviation in the objects or purposes for which the funds have been raised or  
b) Deviation in the amount of funds actually utilized as against what was originally disclosed or  
c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

Date : 24.10.2020  
Place : Mumbai

For ROSSARI BIOTECH LIMITED  
Sd/-  
Manasi Nisal  
Chief Financial Officer

Ant Group IPO pricing history's largest: Jack Ma

REUTERS Shanghai, October 24 THE MAMMOTH DUAL listing for Chinese fintech giant Ant Group will be the world's biggest, according to a pricing determined on Friday night, Alibaba founder Jack Ma said on Saturday. "It's the first time that the pricing of such a big listing—the largest in human history—has been determined outside New York City" he told the Bund Summit in the eastern financial hub of Shanghai. "We didn't dare to think about it five years ago, or even three years ago. But a miracle just occurred," he told the audience, which included officials from China's regulators. He did not give exact details of the pricing which is expected to be officially announced next week. Backed by Chinese e-commerce giant Alibaba, Ant plans to list

simultaneously in Hong Kong and on Shanghai's STAR Market in the coming weeks. Sources have said the listing could be worth \$35 billion, surpassing the record set by Saudi Aramco's \$29.4 billion float last December. Ma said the financial and regulatory system stifles innovation, calling for a revamp to extend financial services to more small firms and individuals on the basis of technology—an ethos that Ant is largely based on. He said the global system established after World War II is outdated and too risk-averse, calling the Basel Committee on Banking Supervision "an old men's club" and warning that risks are accumulating in the whole economy. In China, banks still operate with a strong "pawnshop" mentality, demanding collateral and guarantees before lending, a model that will fail to fuel future growth, he said.

**VIKAS MULTICORP LIMITED**  
CIN: L25111DL1995PLC073719  
Regd. Office: G-1 34/1, EAST PUNJABI BAGH, NEW DELHI-110026  
Ph.: 011-40450110 | E-mail: cs@vikasmulticorp.com | URL: www.vikasmulticorp.com

**EXTRACT OF UN-AUDITED FINANCIAL RESULTS (STANDALONE) For the Second Quarter and Half Year Ended September, 30 2020**  
Rs. In Lakhs

| Particulars   | Three Months Ended      |                         |                      | Six Months Ended        |                      |                      | Year Ended |
|---|-------------------------|-------------------------|----------------------|-------------------------|----------------------|----------------------|------------|
|   | 30.09.2020 (Un-audited) | 30.06.2020 (Un-audited) | 30.09.2019 (Audited) | 30.09.2020 (Un-audited) | 30.09.2019 (Audited) | 31.03.2020 (Audited) |            |
| Total income from operations (net)  | 3185.73                 | 365.22                  | 5176.36              | 3550.95                 | 7480.39              | 15538.00             |            |
| Net profit before Exceptional items and tax   | 41.79                   | 10.55                   | 75.29                | 52.34                   | 227.28               | 353.93               |            |
| Net Profit / (Loss) before tax  | 41.79                   | 10.55                   | 75.29                | 52.34                   | 91.97                | 250.62               |            |
| Net profit after tax  | 31.27                   | 7.89                    | 56.53                | 39.17                   | 68.40                | 139.72               |            |
| Total Comprehensive Income for the period   | (441.15)                | 907.20                  | 1227.63              | 466.04                  | (2861.37)            | (3672.60)            |            |
| Equity Share Capital (Rs.)  | 66,34,95,495            | 66,34,95,495            | 66,34,95,495         | 66,34,95,495            | 66,34,95,495         | 66,34,95,495         |            |
| Earnings Per Share (of Rs. 1/- each) (for continuing and discontinued operations) - |                         |                         |                      |                         |                      |                      |            |
| 1. Basic:   | (0.07)                  | 0.14                    | 0.20                 | 0.07                    | (0.43)               | (0.55)               |            |
| 2. Diluted:   | (0.07)                  | 0.14                    | 0.20                 | 0.07                    | (0.43)               | (0.55)               |            |

Notes:  
1. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The full formats of Quarterly ended Financial Result are available on the website of the Stock Exchange (www.bseindia.com) and (www.nseindia.com).  
2. The above results were reviewed by the Audit Committee and were approved by the Board of Directors at their meeting held on 23.10.2020. The Audit has been conducted by statutory auditors of the company and they have issued Limited Review Report.

By order of the Board of Directors  
For Vikas Multicorp Limited  
Sd/-  
Ujjwal Verma  
Company Secretary & Compliance Officer

Date: 23.10.2020  
Place: New Delhi

**ROSSARI BIOTECH LIMITED**  
(AN ISO9001:2005 & 14001:2015 Certified Company)  
CIN : U24100MH2009PLC194818  
Regd. Office : 201 A & B, 2<sup>nd</sup> Floor, Akruvi Corporate Park, L.B.S. Marg, Next to G. E. Gardens, Kanjurmarg (W) Mumbai - 400 078  
T: +91-22-6123 3800 F: +91-22- 25796982 E: info@rossarimail.com W: www.rossari.com

**EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2020**  
INR in Million

| Particulars  | Quarter ended 30th Sept. 2020 | Half Year ended 30th Sept. 2020 | Quarter ended 30th Sept. 2019 |
|--|-------------------------------|---------------------------------|-------------------------------|
|  | Unaudited                     | Unaudited                       | Unaudited                     |
| Total income from operations   | 1716.74                       | 2811.40                         | 1503.32                       |
| Net Profit for the period (before Tax, Exceptional items and/or Extraordinary item)  | 277.86                        | 485.55                          | 236.83                        |
| Net Profit for the period before tax (after Exceptional items and/or Extraordinary item)   | 277.86                        | 485.55                          | 236.83                        |
| Net Profit for the period after tax (after Exceptional items and/or Extraordinary item)  | 207.28                        | 362.22                          | 177.36                        |
| Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)] | 206.74                        | 361.16                          | 177.01                        |
| Paid up Equity Share Capital (Face value of Rs 2 per share)  | 103.86                        | 103.86                          | 44.00                         |
| Other Equity   |                               |                                 |                               |
| Earnings per equity share (in Rs.) ( of Rs. 2/- each)  |                               |                                 |                               |
| Basic (Not annualised)   | 4.07                          | 7.11                            | 3.66                          |
| Diluted (Not annualised)   | 4.02                          | 7.02                            | 3.66                          |

**Additional Information on Standalone Financial Results is as follows**

| Particulars                      | Quarter ended 30th Sept. 2020 | Half Year ended 30th Sept. 2020 | Quarter ended 30th Sept. 2019 |
|----------------------------------|-------------------------------|---------------------------------|-------------------------------|
|                                  | Unaudited                     | Unaudited                       | Unaudited                     |
| (a) Total income from operations | 1737.09                       | 2831.75                         | 1503.32                       |
| (b) Profit Before Tax            | 288.83                        | 494.90                          | 236.32                        |
| (c) Profit After Tax             | 217.85                        | 370.60                          | 176.93                        |

Notes:  
1. The Consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 24th October, 2020. A review of the above interim financial results has been carried out by the statutory auditors.  
2. The above is an extract of detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the Stock Exchange where shares of the Company are listed i.e. www.bseindia.com and www.nseindia.com and also on the website of the Company i.e. www.rossari.com.

For ROSSARI BIOTECH LIMITED  
Sd/-  
SUNIL CHARI  
Managing Director  
DIN:00149083

Place : MUMBAI  
Date : 24<sup>th</sup> OCTOBER, 2020

**BHAGERIA INDUSTRIES LIMITED**  
(CIN : L40300MH1989PLC052574)  
Regd. Office: 1002, 10<sup>th</sup> Floor, Topiwala Centre, Off S.V. Road, Goregaon (W), Mumbai 400 062. Phone: +91-22-4043 6666, Fax: +91-22-4043 6662, Email id: info@bhageriagroup.com Website: www.bhageriagroup.com

**EXTRACT OF THE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR / QUARTER ENDED 30<sup>th</sup> SEPTEMBER, 2020**  
Rs. in Lakhs (Except Figures of EPS)

| Sr. No. | Particulars  | Standalone             |                        |                        |                        |                        |                      | Consolidated           |                        |                        |                        |                        |                      |
|---------|--|------------------------|------------------------|------------------------|------------------------|------------------------|----------------------|------------------------|------------------------|------------------------|------------------------|------------------------|----------------------|
|         |  | For Quarter ended      |                        | For Half year ended    |                        | For Year ended         | For Quarter ended    |                        | For Half year ended    |                        | For Year ended         |                        |                      |
|         |  | 30.09.2020 (Unaudited) | 30.06.2020 (Unaudited) | 30.09.2019 (Unaudited) | 30.09.2020 (Unaudited) | 30.09.2019 (Unaudited) | 31.03.2020 (Audited) | 30.09.2020 (Unaudited) | 30.06.2020 (Unaudited) | 30.09.2019 (Unaudited) | 30.09.2020 (Unaudited) | 30.09.2019 (Unaudited) | 31.03.2020 (Audited) |
| 1       | Total Income from operations (net)   | 1,965.09               | 678.42                 | 1,880.89               | 2,643.51               | 4,205.28               | 7,854.62             | 1,964.89               | 678.42                 | 1,880.89               | 2,643.30               | 4,205.28               | 7,854.62             |
| 2       | Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)   | 1,965.09               | 678.42                 | 1,880.89               | 2,643.51               | 4,205.28               | 7,854.62             | 1,964.89               | 678.42                 | 1,880.89               | 2,643.30               | 4,205.28               | 7,854.62             |
| 3       | Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)  | 1,615.99               | 570.80                 | 1,715.54               | 2,186.80               | 3,417.48               | 6,581.42             | 1,615.79               | 570.80                 | 1,715.54               | 2,186.59               | 3,417.48               | 6,581.42             |
| 4       | Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)   | 1,617.48               | 567.85                 | 1,701.52               | 2,185.33               | 3,400.90               | 6,569.63             | 1,617.27               | 567.85                 | 1,701.52               | 2,185.12               | 3,400.90               | 6,569.63             |
| 5       | Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] | 2,182.21               | 2,182.21               | 2,182.21               | 2,182.21               | 2,182.21               | 2,182.21             | 2,182.21               | 2,182.21               | 2,182.21               | 2,182.21               | 2,182.21               | 2,182.21             |
| 6       | Equity Share Capital   | 2,182.21               | 2,182.21               | 2,182.21               | 2,182.21               | 2,182.21               | 2,182.21             | 2,182.21               | 2,182.21               | 2,182.21               | 2,182.21               | 2,182.21               | 2,182.21             |
| 7       | Reserve (excluding revaluation reserve as shown in the Balance Sheet of Previous Year)   | -                      | -                      | -                      | -                      | -                      | 38,035.27            | -                      | -                      | -                      | -                      | -                      | 38,035.27            |
| 8       | Earning Per Share (Face Value of Rs.5/- each) (Not to be annualized)   |                        |                        |                        |                        |                        |                      |                        |                        |                        |                        |                        |                      |
| 1.      | Basic :  | 3.70                   | 1.31                   | 3.93                   | 5.01                   | 7.83                   | 15.08                | 3.70                   | 1.31                   | 3.93                   | 5.01                   | 7.83                   | 15.08                |
| 2.      | Diluted :  | 3.70                   | 1.31                   | 3.93                   | 5.01                   | 7.83                   | 15.08                | 3.70                   | 1.31                   | 3.93                   | 5.01                   | 7.83                   | 15.08                |

Notes:  
1. The above results have been reviewed by the Audit committee and thereafter approved by the Board of Directors at the meeting held on October 23, 2020. The Statutory Auditors have carried out the limited review.  
2. The above is an extract of the detailed format of Quarterly and half year Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange website (www.bseindia.com) and on Company's website (www.bhageriagroup.com).

For Bhageria Industries Limited  
Sd/-  
Suresh Bhageria  
Chairperson

Place : Mumbai  
Date : 23<sup>rd</sup> October, 2020

